LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Fulgent Genetics Inc

Chiusa

SettoreSettore sanitario

19.55 -0.05

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.27

Massimo

19.81

Metriche Chiave

By Trading Economics

Entrata

-5.7M

-12M

Vendite

-2.8M

73M

EPS

0.04

Margine di Profitto

-16.197

Dipendenti

1,313

EBITDA

-2M

-12M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+22.64% upside

Dividendi

By Dow Jones

Utili prossimi

1 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

23M

595M

Apertura precedente

19.6

Chiusura precedente

19.55

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Fulgent Genetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 giu 2025, 23:49 UTC

Utili

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 giu 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 giu 2025, 21:30 UTC

Utili

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Utili

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 giu 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 giu 2025, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 giu 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 giu 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 giu 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 giu 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 giu 2025, 23:19 UTC

Acquisizioni, Fusioni, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 giu 2025, 22:06 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:15 UTC

Utili

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 giu 2025, 21:07 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 giu 2025, 21:06 UTC

Discorsi di Mercato

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 20:52 UTC

Utili

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 giu 2025, 20:51 UTC

Utili

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Fulgent Genetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

22.64% in crescita

Previsioni per 12 mesi

Media 24 USD  22.64%

Alto 25 USD

Basso 23 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Fulgent Genetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

17.32 / 19.04Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

154 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.